StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Q1 Launch update on Twitter and LinkedIn

<< Previous

Bullboard Posts

Next >>

Post by LithLoveron Dec 18, 2020 12:37am

329 Views

Post# 32137836

Q1 Launch update on Twitter and LinkedIn

I totally missed this posted on LinkedIn and Twitter. Posted 9 hours ago.

StageZero Life Sciences’ Aristotle 10 in 1 cancer screening test looks set to launch in Q1 2021

https://ow.ly/41ae50COzMJ

and than they added the investorintel link article.

no way they would be posting that on Social media if it wasn't close to launch.